Subtract HDL cholesterol from total cholesterol and you have a cardiovascular risk number that costs nothing. Of the cardiovascular markers we cover, it is the only one that needs no extra test, no fasting sample and no equation that can break.
The Verdict
How to Work It Out from Your Own Panel
Take the total cholesterol value and subtract the HDL cholesterol value. Total cholesterol of 210 mg/dL minus an HDL of 55 mg/dL gives a non-HDL of 155 mg/dL. Both numbers are directly measured, so nothing about the result depends on an assumption.
That is the difference between non-HDL and the LDL line beside it. LDL cholesterol on a standard panel is usually calculated, and the calculation assumes a fixed relationship between triglycerides and the cholesterol inside very low density lipoprotein particles. When triglycerides run high the assumption fails and most laboratories suppress the LDL line entirely. The subtraction behind non-HDL keeps working at any triglyceride level.
Our page on what a lipid panel measures covers which lines are measured and which are estimated on the report you are holding.
What Non-HDL Cholesterol Counts
Every lipoprotein particle in your blood carries cholesterol, and only one class of them is thought not to drive plaque. High density lipoprotein is that class. Subtracting it therefore leaves the cholesterol carried by everything that can enter an artery wall.
That total includes low density lipoprotein, very low density lipoprotein, intermediate density lipoprotein, chylomicron remnants and Lp(a). LDL is the largest share of it in most people, which is why LDL and non-HDL usually agree. The gap between them widens as triglyceride-rich particles multiply.
Those remnant particles are the reason the number exists as a target at all. They carry cholesterol, they enter the artery wall, and the LDL line does not count them.
Targets, and Where the 30 mg/dL Comes From
Guideline non-HDL targets sit exactly 30 mg/dL above the corresponding LDL target. The National Heart, Lung, and Blood Institute Adult Treatment Panel introduced that convention when it added non-HDL as a secondary treatment goal for people with triglycerides above 200 mg/dL. The two rows above it use that panel's figures, and the very-high-risk row uses the tighter European targets.
| Risk category | LDL target | Non-HDL target | Who this describes |
|---|---|---|---|
| General population, no risk factors | Under 100 mg/dL | Under 130 mg/dL | The screening reference for an adult with no cardiovascular disease |
| Diabetes, or multiple risk factors | Under 70 mg/dL | Under 100 mg/dL | The band most people on a statin are being treated into |
| Established cardiovascular disease | Under 55 mg/dL | Under 85 mg/dL | The very-high-risk targets in the 2019 European Society of Cardiology and European Atherosclerosis Society guideline |
The 30 mg/dL offset represents the cholesterol normally carried in triglyceride-rich particles at a triglyceride level of about 150 mg/dL. In someone whose triglycerides sit well above that, the real gap is wider, and the non-HDL number is doing more work than the offset suggests.
Non-HDL Against LDL and ApoB
Three numbers compete to answer the same question, and they differ in cost and in what they physically count.
| Marker | What it costs | What it does well | Where it falls down |
|---|---|---|---|
| Non-HDL cholesterol | Free, on every panel | Total minus HDL, no assumptions | Measures cholesterol mass rather than particle number |
| LDL cholesterol | Free, on every panel | The number every guideline and trial is written around | Usually calculated, and the calculation fails above 400 mg/dL of triglycerides |
| ApoB | Ordered separately, roughly $20 to $40 | Counts atherogenic particles directly, the best of the three at predicting events | Not on standard panels, and not covered by every insurer |
Read together, the order is straightforward. Calculate non-HDL from the panel you already have, because it is free and better than the LDL line beside it. Add ApoB when you want the strongest available answer, particularly if triglycerides are high or you have a family history of early heart disease. Our page on the ApoB blood test covers what that adds and what it costs.
What Moves Non-HDL Cholesterol
Non-HDL responds to everything that lowers LDL, plus the interventions that work on triglycerides. Statins reduce it by roughly 30% to 50% depending on the drug and dose, and adding ezetimibe reduces it a further 15% to 20%. Further out, a CRISPR edit of the ANGPTL3 gene reported a 52.5 percent mean LDL reduction at one year at its highest dose of 0.8 mg/kg. Fifteen adults were spread across five dose levels, so that figure rests on three or four of them, and there was no control group.
On the non-drug side, the useful distinction is that non-HDL rewards changes LDL barely registers. Cutting alcohol lowers triglycerides within days and pulls non-HDL down with them. Weight loss and reduced refined carbohydrate intake do the same over weeks. Soluble fibre from oats, legumes and psyllium contributes a few percentage points, as do plant sterols.
Allow six to eight weeks between a change and a retest. Lipids take that long to settle, and a panel drawn at three weeks describes the transition.
Who Should Not Rely on This Number
Anyone whose triglycerides are consistently above 400 mg/dL is in territory where non-HDL still functions but the underlying disorder needs a physician rather than a target. Very high triglycerides carry a pancreatitis risk that no cholesterol number describes.
Anyone with a strong family history of early cardiovascular disease should not stop at non-HDL either. A one-time Lp(a) measurement answers a question no calculated value can, since Lp(a) is inherited, largely fixed for life, and hidden inside both the LDL and the non-HDL totals.
What would change our answer is ApoB appearing on standard panels at standard prices. It counts particles rather than estimating their cargo, and it would make non-HDL a fallback rather than a recommendation. Until that happens, work out your own non-HDL from your last report, compare it against the target for your risk category, and take both numbers to your next appointment.
Frequently Asked Questions
How do you calculate non-HDL cholesterol?
Subtract HDL cholesterol from total cholesterol. Total cholesterol of 210 mg/dL with an HDL of 55 mg/dL gives a non-HDL of 155 mg/dL. There is no correction factor, no assumption about particle composition, and no equation that stops working at high triglycerides. Both numbers come from the same panel, so you can work it out from any lipid report you already have.
What is a good non-HDL cholesterol level?
Under 130 mg/dL is the general reference for an adult with no cardiovascular disease. Under 100 mg/dL is the usual target for someone with diabetes or several risk factors. Under 85 mg/dL is the very-high-risk target in the 2019 European Society of Cardiology and European Atherosclerosis Society guideline. The rule behind those figures is simple: each non-HDL target sits 30 mg/dL above the matching LDL target, because that 30 mg/dL represents the cholesterol carried in triglyceride-rich particles.
Is non-HDL cholesterol better than LDL?
For predicting cardiovascular events, yes, particularly in anyone with raised triglycerides. LDL cholesterol counts only the cholesterol inside LDL particles. Non-HDL counts the cholesterol in every particle that can enter an artery wall, which adds very low density lipoprotein, intermediate density lipoprotein, remnant particles and Lp(a). In people with diabetes or metabolic syndrome, where those remnant particles are abundant, LDL can look controlled while non-HDL is clearly not.
Do you need to fast to measure non-HDL cholesterol?
No, and this is one of its practical advantages. Total cholesterol and HDL both move very little after a meal, so their difference holds up in a non-fasting sample. Calculated LDL does not, because the equation subtracts a fifth of the triglyceride value and a recent meal inflates that. Our page on fasting for a lipid panel covers what each line does after you eat.
Why is non-HDL cholesterol not on my lab report?
Many laboratories print it and some still do not, largely by convention rather than for any technical reason. If yours does not, calculate it yourself from the two lines that are there. Ask the laboratory to include it. Non-HDL also stays comparable when you switch laboratories, while a calculated LDL can shift by 10 to 15 mg/dL when the equation changes.
How does non-HDL cholesterol compare to ApoB?
They track each other closely and answer slightly different questions. Non-HDL measures the cholesterol mass carried in atherogenic particles. ApoB counts the particles themselves, since each carries exactly one ApoB molecule. Where the two disagree, which happens in people carrying many small cholesterol-poor particles, ApoB is the better predictor. Non-HDL is the sensible free approximation when ApoB is not available, and it is not a reason to skip ApoB when it is.
What lowers non-HDL cholesterol?
Everything that lowers LDL lowers non-HDL, and a few things that do not. Statins reduce it by 30% to 50% depending on dose and drug. Ezetimibe adds a further 15% to 20%. Because non-HDL includes triglyceride-rich particles, weight loss, reduced alcohol intake and lower refined carbohydrate intake move it more than they move LDL alone. Soluble fibre and plant sterols each contribute a few percentage points, covered on our page about foods that lower cholesterol.
Can non-HDL be high when LDL is normal?
Yes, and that combination is the single most useful thing this number tells you. It happens when triglyceride-rich remnant particles are carrying cholesterol that the LDL line does not count. Someone with an LDL of 95 mg/dL, triglycerides of 250 mg/dL and an HDL of 38 mg/dL has a non-HDL around 145 mg/dL and a real risk their LDL value understates. That pattern almost always points at insulin resistance, and the triglyceride to HDL ratio confirms it from the same panel.